Medtronic : A Conversation and Question & Answer Session with Rebecca Seidel, VP & General Manager, AF Solutions, Medtronic plc
July 01, 2020 at 07:29 pm EDT
Share
WELCOME
THANK YOU FOR JOINING THE MEDTRONIC INVESTOR RELATIONS TEAM FOR
A CONVERSATION AND QUESTION & ANSWER SESSION WITH:
REBECCA SEIDEL
Vice President & General Manager, Cardiac Ablation Solutions (CAS)
Moderated by
RYAN WEISPFENNING
Vice President & Head of Investor Relations
WE WILL BEGIN SHORTLY . . .
JULY 1, 2020
LOGISTICS
To participate in the Q&A session and ask a live question, you will need to join via the WebEx platform versus only dialing-in
Enter the Event ID:145 935 9870andEnter your Nameso we can identify you. We can't call on you unless your name is clearly entered
To ask a question you have to "raise your hand" in the participants panel
2
MEDTRONIC ARCTIC FRONT ADVANCE PRO™CRYOBALLOONSETTING THE STANDARD FOR ANATOMICAL ABLATION
Achieve Advance™ MappingCatheter
The world's leadingballoon therapy for the treatment of drug refractory recurrent symptomatic paroxysmal AF.
Arctic Front Advance Pro™ Cryoballoon
FlexCath Advance™ SheathCryoConsoleTM
1) Packer, et al. Cryoballoon Ablation of Pulmonary Veins for Paroxysmal Atrial Fibrillation: First Results of the North American Arctic Front (STOP AF) Pivotal Trial. J Am Coll Cardiol. April 23, 2013;61(16):1713-1723. 2) Kuck KH, et al. Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2016; 374(23): 2235-45. 3) Providencia R., et al.EP Europace. January 2017;19(1):48-57 4) Wójcik M, Berkowitsch A, Greis H, et al. Learning curve in cryoballoon ablation of atrial fibrillation.Circ J.2014;78:1612-8.
Anatomicalapproach to Pulmonary Vein Isolation that has been proven safe and effective1.
Efficient,predictableprocedures with a minimal learning curve3,4.
Single transseptalpuncture needed; Achieve Mapping catheter deployed through Arctic Front Advance guidewire lumen.
THE DIAMONDTEMP ABLATION SYSTEM WITH REALTEMP
*NOT APPROVED FOR USE IN THE US
•80% freedom from AF at 6 months (Paroxysmal and Persistent)1.
•Catheter tip-surface thermocouples aimed to permit fast, safe and effective temperature-controlled, saline-irrigated RF ablation2.
•RealTemp is the groundbreaking power of real-time temperature control available only with the
DiamondTemp Ablation System.
•The TRAC-AF study showed real-time temperature controlled ablation enabled a 70% reduction in
RF application time when compared with a conventional, irrigated RF catheter with contact force2.
1Neužil et al. First-in-Man FASTR-AF Study: Novel Temperature-Controlled FAST Ablation System to Rapidly Create Lesions for the Treatment of Persistent and Paroxysmal Atrial Fibrillation. HRS Scientific Sessions, 2019.
2Iwasawa J, et al.J Am Coll Cardiol. 2017;70:542-553.
*Not approved or available for sale/distribution in all geographies; CE mark approval has been granted. The products
5
described above are not approved by the FDA for any use and not commercially available in the U.S..
Attachments
Original document
Permalink
Disclaimer
Medtronic plc published this content on 01 July 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 July 2020 23:28:02 UTC
Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows:
- general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.;
- cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.;
- vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.;
- spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity;
- neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%);
- diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps;
- neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc.
Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).
MEDTRONIC PLC 
